Cytokinetics We recently became enthusiastic about Cytokinetics’ (CYTK) current clinical trial results. A few days ago, Cytokinetics announced positive results from SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Why the Great Enthusiasm? The following has been behind our enthusiasm . . . This …
Sarepta Therapeutics in the NEWS On 12, 22, 2023, Sarepta Therapeutics (SRPT) - a precision genetic medicine for rare diseases, announced submission of an efficacy supplement to the Biologics License Application (BLA) for ELEVIDYS (delandistrogene moxeparvovec-rokl) to expand its labeled indication as follows: “ELEVIDYS is indicated for] the treatment of Duchenne muscular dystrophy (DMD) patients with a confirmed . . . This content is for paid …
The information is the first of a few biotech Companies that we believe are promising in treating severe devastating untreatable sicknesses. Arcturus Therapeutics Holdings Based in San Diego, California, Arcturus Therapeutics Holdings (ARCT) was founded in 2013. The Company is a late-stage clinical developing novel mRNA medicines and vaccines which already demonstrated promising results in early trials. The Company is creating . . . This content …
Anavex Life Sciences Promising News From Anavex Life Sciences (AVXL) we learned that The Committee for Medicinal Products for Human Use (CHMP) within the European Medicines agency (EMA) agreed that oral blarcamesine for Alzheimer’s disease is eligible for submission of application for a Union Marketing Authorization in the EU under the European Medicines Agency’s centralized procedure . . . This content is for paid subscribers. Please click here …
Merck & Invivyd in the NEWS Our post today comprises a premarket drug rejection. An important new approval for Merck's (MRK) Keytruda product, and exciting promising trial results for the firm Invivyd, Inc. (
Prohost Letter #458 ~ Obesity Finally, obesity is being recognized as a severe sickness. Indeed, obesity is several devastating diseases, which include cardiovascular diseases, high blood pressure, Type 2 diabetes, cancers, sleep apnea, breathing problems, and more. Many studies demonstrated that effective treatments for the disease will treat all these sicknesses. The good news is that we already have effective treatments. Part of the effective …
Editas Medicine and Vertex Pharmaceuticals in the NEWA Today December 13, 2023, Editas Medicine (EDIT) announced that it entered into an agreement with Vertex Pharmaceuticals (
Vertex Pharmaceuticals in the NEWS Today, December 13, 2023, Vertex Pharmaceuticals (VRTX) announced positive results from its Phase 2 dose-ranging study of the selective NaV1.8 inhibitor VX-548 in people with painful diabetic peripheral neuropathy (DPN). Treatment with all . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Crispr Therapeutics and Vertex Pharmaceuticals Gene Editing Therapey Will Be Marketed On Nov. 16, 2023, Crispr Therapeutics (CRSP) and Vertex Pharmaceuticals (VRTX)
Novartis Approval Novartis (NVS) product Fabhalta (iptacopan) is a Factor B inhibitor that acts in the proximate alternative complement pathway of the immune system, It provides comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis. Fabhalta treatment of paroxysmal nocturnal hemoglobinuria (PNH) increased hemoglobin levels (≥ 2 g . . . This content is for paid …
Roche in the NEWS From Basel, today, December 5, 2023 - Roche (RHHBY) announced positive results from the Phase III INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance®) and fulvestrant as a potential first-line treatment option for people with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast . . . This content is for paid subscribers. Please click here to …
EyePoint Pharmaceuticals Treating Wet Age-Related Macular Degeneration In today's press release, EyePoint Pharmaceuticals (EYPT) announced positive topline results of its Phase 2 DAVIO 2 trial of EYP . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Altimmune Positive Topline Results Altimmune (ALT) announced positive results from the MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide. Altimmune is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver fibrosis. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist developed for treating obesity and metabolic dysfunction-associated steatohepatitis (MASH
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
